Search

Your search keyword '"Finke, Christy"' showing total 250 results

Search Constraints

Start Over You searched for: Author "Finke, Christy" Remove constraint Author: "Finke, Christy" Database Unpaywall Remove constraint Database: Unpaywall
250 results on '"Finke, Christy"'

Search Results

1. PTPN11variants in chronic myelomonocytic leukemia: Phenotypic and prognostic correlates.

2. The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance

3. Pilot Prospective Study of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Vexas Syndrome

5. Patients with telomere biology disorders show context specific somatic mosaic states with high frequency of U2AF1 variants

7. Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy

8. Supplementary Table S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

9. Supplementary Figure S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

11. Supplementary Data S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

12. Data from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

13. Data from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

14. Supplementary Table S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

15. Supplementary Figure S7 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

16. Supplementary Figure S3 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

17. Supplementary Table S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

18. Supplementary Figure S3 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

19. Supplementary Figure S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

20. Supplementary Figure S6 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

21. Supplementary Table S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

22. Supplementary Data S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

23. Supplementary Table S3 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

24. Supplementary Figure S4 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

25. Supplementary Figure S6 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

26. Supplementary Table S3 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

27. Supplementary Figure S5 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

28. Supplementary Figure S7 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

29. Supplementary Figure S4 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

30. Supplementary Figure S5 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

32. Supplementary Figure S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

33. Supplementary Data S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

34. Supplementary Figure S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

35. Supplementary Data S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

36. Supplementary Figure S5 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

37. Supplementary Figure S4 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

38. Supplementary Figure S4 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

39. Supplementary Figure S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

40. Supplementary Figure S6 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

41. Supplementary Figure S3 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

42. Supplementary Figure S7 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

43. Supplementary Figure S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

44. Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

45. Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms

46. Spectrum of clonal hematopoiesis in VEXAS syndrome

47. Abstract 806: Enhancer deregulation inTET2-mutant clonal hematopoiesis is associated with increased COVID-19 severity and mortality

48. Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease

49. Clinical and molecular spectrum and prognostic outcomes of U2AF1 mutant clonal hematopoiesis- a prospective mayo clinic cohort study

50. Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients

Catalog

Books, media, physical & digital resources